NervGen Pharma Corp. Stock: price and insider trades · Canada
NervGen Pharma Corp.: what insiders have been doing
Every trade that managers of NervGen Pharma Corp. disclose to SEDI is tracked on this page. The company sits in the Health Care sector. In the past year (24 October 2025 to 24 October 2026), 42 filings came from 9 insiders.
Purchases and sales both appear in the filings: 4 purchases (2 insiders, €22k) and 11 sales (1 insider, €204k). The net balance comes to €183k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. McKerracher, Krista filed the largest sale, €27k, on 23 February 2026. The buyers include 2 senior executives.
The most recent open-market purchase was published on 5 August 2026, 96 days ago. Typically, a trade is published a median of 5 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 42 filings in twelve months, the company is more active than the median of 14 filings across the 2,734 companies we follow on the same exchange. Since 2019, the database holds 5 purchases and 20 sales by insiders of the company.
This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 55,000 shares@ CA$2.3244.9% of flowOptionsTSXSEDI:4775677
- 55,000 shares@ CA$2.32100.0% of flowOptionsTSXSEDI:4775662
- 55,000 shares@ CA$2.3246.1% of flowOptionsTSXSEDI:4775658
- 55,000 shares@ CA$2.3287.3% of flowOptionsTSXSEDI:4775655
- 55,000 shares@ CA$2.32100.0% of flowOptionsTSXSEDI:4775652
- 55,000 shares@ CA$2.3210.9% of flowOptionsTSXSEDI:4775646
- 17,178 shares@ CA$2.103.1% of flowCommon SharesTSXSEDI:4775644
- 50,000 shares@ CA$2.108.9% of flowOptionsTSXSEDI:4775643
- 55,000 sharesOptionsTSXSEDI:4774792
- 50,000 shares@ CA$2.109.7% of flowOptionsTSXSEDI:4774786
- 17,627 shares@ CA$2.100.0060% mcap13.7% of flowCommon SharesTSXSEDI:4770513
- Common SharesTSXSEDI:4770511
- 50,000 shares@ CA$2.1038.9% of flowOptionsTSXSEDI:4770507
- 8,974 shares@ CA$2.100.0031% mcap7.5% of flowCommon SharesTSXSEDI:4770502
- 50,000 shares@ CA$2.1041.6% of flowOptionsTSXSEDI:4770501
- 200 shares@ CA$1.640.0001% mcap0.2% of flowCommon SharesTSXSEDI:4759712Canonical exit: 26 Oct 2026 (T+90)
- Common SharesTSXSEDI:4759711
- 61,713 shares@ CA$3.640.036% mcap2.3% of flowCommon SharesTSXSEDI:4748874
- 37,784 shares@ CA$3.640.022% mcap1.4% of flowCommon SharesTSXSEDI:4748871
- 812,002 shares@ CA$3.92100.0% of flowOptionsTSXSEDI:4729336
- OptionsTSXSEDI:4729329
- 800,000 shares@ CA$3.6829.8% of flowWarrantsTSXSEDI:4727977
- 800,000 shares@ CA$2.5020.3% of flowCommon SharesTSXSEDI:4727973
- 16 shares@ CA$2.07620.0% of flowCommon SharesTSXSEDI:4725857Canonical exit: 25 Aug 2026 (T+90)
- 8,775 shares@ CA$2.07812.5% of flowCommon SharesTSXSEDI:4725855Canonical exit: 25 Aug 2026 (T+90)
25 of 98 declarations
About NervGen Pharma Corp.
NervGen Pharma Corp. is a biopharmaceutical company focused on developing treatments for neurological diseases. It is listed on the Toronto Stock Exchange under the symbol XTSE.
